Diaxonhit

As a result of the acquisition of InGen BioSciences by Exonhit, the new Diaxonhit group benefits from the complementary capabilities derived from both companies’ business models. Its growth is based on the continued development of its distribution activities, and the development of its high added value proprietary innovative diagnostic products.
Diaxonhit owns a broadened and diversified portfolio of proprietary diagnostic products in three specialty areas : transplantation, infectious diseases and cancer diagnosis.
The group is currently marketing two proprietary products, TQS® (Tetanus Quick Stick) for the evaluation of patients’ immune status against tetanus, and BJI Inoplex for the diagnosis of bone joint prosthetic infections. The group also commercializes AlloMap, a molecular test for the surveillance of heart-transplant patients, under an exclusive licence for Europe.

Type
Public
HQ
Paris, FR
Founded
1997
Employees
89 (est)
Diaxonhit was founded in 1997 and is headquartered in Paris, FR

Diaxonhit Locations

Paris, FR
Rockville, US

Diaxonhit Metrics

Diaxonhit Summary

Market capitalization

€23 M

Closing share price

€0.3
Diaxonhit's latest market capitalization is €23 M.

Diaxonhit Market Value History

Diaxonhit Company Life